Effect of autologous adipose-derived mesenchymal stem cell therapy in the treatment of acromioclavicular joint osteoarthritis.
TL;DR: This case is the first to show the benefit of MSC therapy in the treatment of small joint arthropathy and also of the upper limb.
read more
Abstract: The aim of this case report is to evaluate the efficacy of mesenchymal stem cell (MSC) therapy in the treatment of small joint osteoarthritis (OA). Acromio-clavicular (AC) joint OA is an under-diagnosed and yet frequent source of shoulder pain. MSCs have shown evidence of benefit in the treatment of knee OA. This is the first report to describe the use of MSC therapy in OA of the upper limb. A 43-year-old patient presents with painful AC joint OA and undergoes MSC therapy. The patient reported pain and functional improvement as assessed by the Disability of Arm, Shoulder and Hand Score and Numeric Pain Rating Scale. Imaging at 12 months showed structural improvement with reduction in subchondral oedema, synovitis and subchondral cysts. This case is the first to show the benefit of MSC therapy in the treatment of small joint arthropathy and also of the upper limb.Trial registration number: Australian New Zealand Clinical Trials Registry (ACTRN12617000638336).
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients.
Christopher J. Rogers,Robert J. Harman,Bruce A. Bunnell,Martin A. Schreiber,Charlie Xiang,Fu Sheng Wang,Antonio F. Santidrian,Boris Minev +7 more
TL;DR: Adipose-derived stem cells (ASC), an abundant type of MSC, are proposed as a therapeutic option for the treatment of COVID-19 in order to reduce morbidity and mortality and when proven to be safe and effective, ASC treatments may reduce the demand on critical hospital resources.
Arthroscopic Rotator Cuff Repair Augmentation With Autologous Microfragmented Lipoaspirate Tissue Is Safe and Effectively Improves Short-term Clinical and Functional Results: A Prospective Randomized Controlled Trial With 24-Month Follow-up
Pietro Randelli,Davide Cucchi,Chiara Fossati,Linda Boerci,Elisabetta Nocerino,Federico Ambrogi,Alessandra Menon +6 more
TL;DR: This prospective randomized controlled trial demonstrated that the intraoperative injection of autologous microfragmented adipose tissue is safe and effective in improving short-term clinical and functional results after single-row arthroscopic rotator cuff repair.
21
Real-world evidence of mesenchymal stem cell therapy in knee osteoarthritis: a large prospective two-year case series.
TL;DR: ADMSC therapy is an effective, safe and long-lasting treatment option for knee OA with the potential to delay total joint replacement and promises to reduce the global economic burden of OA.
17
Evaluation of autologous adipose-derived mesenchymal stem cell therapy in focal chondral defects of the knee: a pilot case series.
TL;DR: Arthroscopic abrasion arthroplasty in combination with intra-articular ADMSC therapy results in reproducible pain, functional and structural improvements with regeneration of hyaline-like cartilage.
17
Modulation of T-Cell Activation Markers Expression by the Adipose Tissue-Derived Mesenchymal Stem Cells of Patients with Rheumatic Diseases
Ewa Kuca-Warnawin,I Janicka,Piotr Szczęsny,Marzena Olesińska,Krzysztof Bonek,Piotr Głuszko,Ewa Kontny +6 more
TL;DR: RD/ASCs retain normal capability to regulate expression of activation markers on allogeneic T cells, and autologous CD4+ and CD8+ T cells are partially resistant to RD/asCs inhibition of CD25 expression, suggesting weaker control of T-cell activation in vivo.
16
References
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement
Massimo Dominici,K. Le Blanc,Ingo Mueller,I. Slaper-Cortenbach,Frank C. Marini,Diane S. Krause,Robert J. Deans,Armand Keating,Darwin J. Prockop,Edwin M. Horwitz +9 more
TL;DR: The Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy proposes minimal criteria to define human MSC, believing this minimal set of standard criteria will foster a more uniform characterization of MSC and facilitate the exchange of data among investigators.
17.5K
Human Adipose Tissue Is a Source of Multipotent Stem Cells
Patricia A. Zuk,Min Zhu,Peter Ashjian,Daniel A. De Ugarte,Jerry I. Huang,Hiroshi Mizuno,Zeni Alfonso,John K. Fraser,Prosper Benhaim,Marc H. Hedrick +9 more
TL;DR: To confirm whether adipose tissue contains stem cells, the PLA population and multiple clonal isolates were analyzed using several molecular and biochemical approaches and PLA cells exhibited unique characteristics distinct from those seen in MSCs, including differences in CD marker profile and gene expression.
Sox9 Modulates Proliferation and Expression of Osteogenic Markers of Adipose-Derived Stem Cells (ASC)
TL;DR: A pro-proliferative role for Sox9 in undifferentiated rASC is suggested which may explain the higher proliferation rate of rASC compared to rBMSC and an osteogenic differentiation delaying role of Sox9 is proposed which suggests that Sox9 expression is needed to maintain rASC in an undifferentiate, proliferative state.
Core outcome domains for chronic pain clinical trials: IMMPACT recommendations.
Dennis C. Turk,Robert H. Dworkin,Robert R. Allen,Nicholas Bellamy,Nancy A. Brandenburg,Daniel B. Carr,Charles S. Cleeland,Raymond A. Dionne,John T. Farrar,Bradley S. Galer,David J. Hewitt,Alejandro R. Jadad,Nathaniel P. Katz,Lynn D. Kramer,Donald C. Manning,Cynthia McCormick,Michael P. McDermott,Patrick J. McGrath,Steve Quessy,Bob A. Rappaport,James P. Robinson,Mike A. Royal,Lee S. Simon,Joseph W. Stauffer,Wendy M. Stein,Jane Tollett,James Witter +26 more
TL;DR: In this article, the authors provide recommendations for the core outcome domains that should be considered by investigators conducting clinical trials of the efficacy and effectiveness of treatments for chronic pain, and develop a core set of outcome domains would facilitate comparison and pooling of d
3.8K
Topical Review and RecommendationsCore outcome measures for chronic pain clinical trials: IMMPACT recommendations
Robert H. Dworkin,Dennis C. Turk,John T. Farrar,Jennifer A. Haythornthwaite,Mark P. Jensen,Nathaniel P. Katz,Robert D. Kerns,Gerold Stucki,Robert R. Allen,Nicholas Bellamy,Daniel B. Carr,Julie Chandler,Penney Cowan,Raymond A. Dionne,Bradley S. Galer,Sharon Hertz,Alejandro R. Jadad,Lynn D. Kramer,James Witter +18 more
3.2K
Related Papers (5)
Mohsen Emadedin,Maede Ghorbani Liastani,Roghayeh Fazeli,Fatemeh Mohseni,Reza Moghadasali,Soura Mardpour,Seyyedeh Esmat Hosseini,Maryam Niknejadi,Fatemeh Moeininia,Aslan Aghahossein Fanni,Reza Baghban Eslaminejhad,Ahmad Vosough Dizaji,Narges Labibzadeh,Ali Mirazimi Bafghi,Hossein Baharvand,Nasser Aghdami +15 more